Welcome to our dedicated page for Vir Biotechnology news (Ticker: VIR), a resource for investors and traders seeking the latest updates and insights on Vir Biotechnology stock.
Vir Biotechnology, Inc. (VIR) pioneers immunology solutions targeting complex infectious diseases through innovative platforms including antibody therapies, T cell engineering, and siRNA technology. This dedicated news hub provides investors and industry stakeholders with timely updates on clinical developments, strategic partnerships, and regulatory milestones.
Access authoritative updates on VIR's research pipeline, financial performance announcements, and scientific breakthroughs in infectious disease management. Our curated collection ensures transparent access to press releases spanning clinical trial progress, collaborative initiatives, and patent filings.
Key updates include advancements in hepatitis B/HIV therapies, influenza A research, and platform technology licensing agreements. Bookmark this page to efficiently monitor VIR's contributions to biotechnology and its evolving position in global health innovation.
The European Medicines Agency’s CHMP has provided a positive scientific opinion regarding the early treatment of COVID-19 with sotrovimab (previously VIR-7831). This opinion permits EU member states to consider early use of the drug prior to formal EMA marketing authorization. The opinion followed a review of the Phase 3 COMET-ICE trial, which showed an 85% reduction in hospitalization or death among treated patients. Discussions with regulators in other countries for potential authorizations are ongoing, emphasizing the urgency of effective COVID-19 treatments amid rising variants.
Vir Biotechnology and GlaxoSmithKline announced a positive scientific opinion from the EMA’s Committee for Human Medicinal Products for sotrovimab, a treatment for COVID-19, particularly in adults and adolescents at risk of severe disease. EU member states can utilize this opinion for early use decisions before formal marketing authorization. Sotrovimab is set to be available for patients in the U.S. soon. The CHMP's decision was based on an interim analysis from the Phase 3 COMET-ICE trial, demonstrating an 85% reduction in hospitalization or death, highlighting its efficacy against evolving COVID-19 variants.
Vir Biotechnology (Nasdaq: VIR) will hold its 2021 Annual General Meeting of Stockholders on May 20, 2021, at 11:30 a.m. PT, in a virtual format only. Stockholders of record as of March 22, 2021, can attend by accessing the meeting center online. Stockholders are encouraged to vote and submit their proxy ahead of the meeting. Vir Biotechnology specializes in immunology, focusing on solutions for serious infectious diseases, with a pipeline targeting COVID-19, hepatitis B, influenza A, and HIV.
Vir Biotechnology and GSK announced that the European Medicines Agency (EMA) has initiated a rolling review of sotrovimab, an investigational monoclonal antibody for treating COVID-19 in high-risk adults and adolescents. This review supports an upcoming Marketing Authorization Application. The EMA's assessment will consider data, including interim analyses from the Phase 3 COMET-ICE trial, where sotrovimab showed an 85% reduction in hospitalizations compared to placebo. The review process aims to expedite the authorization of sotrovimab for COVID-19 treatment.
Vir Biotechnology reported first-quarter results as of March 31, 2021, noting total revenues of $2 million, a decrease from $5.7 million in Q1 2020. Research and development expenses surged to $134.9 million, reflecting costs for COVID-19 programs, particularly VIR-7831 and VIR-2218. The net loss widened to $168.9 million, or $1.32 per share, compared to $77.2 million, or $0.71 per share, in the previous year. The company holds $733 million in cash and equivalents, bolstered by a recent equity sale to GSK. Upcoming trials and regulatory submissions highlight ongoing efforts to combat COVID-19.
Vir Biotechnology, Inc. (Nasdaq: VIR) will release its corporate update and financial results for Q1 2021, ending March 31, 2021, on May 6, 2021. The update will be available through a press release after market close on the company's website. Vir Biotechnology focuses on treating serious infectious diseases through innovative immunological technologies, developing candidates targeting COVID-19, hepatitis B, influenza A, and HIV.
Vir Biotechnology, Inc. (NASDAQ: VIR) announces the dosing of its first patient in a Phase 2 clinical trial for chronic hepatitis B (HBV). The trial evaluates the combination of BRII-835 (VIR-2218), an RNA-targeted therapeutic, with BRII-179 (VBI-2601), an HBV immunotherapeutic. This marks the first evaluation of these dual mechanisms in HBV treatment, aiming for a functional cure. The study spans multiple countries, including Australia and China, and is sponsored by Brii Biosciences.
Brii Biosciences, Vir Biotechnology, and VBI Vaccines have commenced a Phase 2 clinical trial for BRII-835 (VIR-2218) and BRII-179 (VBI-2601) aimed at treating chronic hepatitis B virus (HBV) infection. This landmark trial investigates the combination of an siRNA targeting HBV and an HBV immunotherapeutic, marking the first clinical evaluation of this dual-action approach. The study is multi-centered across several countries in Asia and Oceania, focusing on safety and efficacy. Leading experts express optimism about achieving a functional cure for HBV through this innovative combination.
Vir Biotechnology and GSK announced progress in discussions with global regulators for VIR-7831, a monoclonal antibody for treating COVID-19. The European Medicines Agency (EMA) has commenced a review, using interim data from the Phase 3 COMET-ICE trial, which showed an 85% reduction in hospitalization or death. VIR-7831 received a provisional determination from Australia’s TGA, the first for an anti-SARS-CoV-2 monoclonal antibody. An Emergency Use Authorization application is pending with the FDA.
Vir Biotechnology, Inc. (Nasdaq: VIR) published new preclinical research demonstrating how SARS-CoV-2 enters host cells and how auxiliary receptors may impact monoclonal antibodies (mAbs) efficacy. The study identifies three auxiliary receptors that enhance infection, with SIGLEC1 being notably important in severe COVID-19 cases. The research reveals that non-RBM-targeting antibodies, such as VIR-7831 and VIR-7832, show enhanced neutralizing activity compared to RBM-targeting antibodies. These findings support the potential of these investigational mAbs in treating and preventing COVID-19.
